Luteal oxytocin receptor antagonist therapy for implantation and pregnancy in women undergoing assisted reproduction

摘要

The present invention relates to the use of oxytocin receptor antagonists in women undergoing embryo transfer as part of assisted reproduction. In particular, methods are provided for increasing continuous implantation rate, increasing continuous pregnancy rate, increasing clinical pregnancy rate, and / or increasing production rate in female subjects undergoing embryo transfer. Specifically, the antagonist is released in the luteal phase when the endometrium is receptive for embryo implantation and / or when the embryo reaches the blastocyst stage.